AP2B1

Across TCGA pan-cancer cohorts, AP2B1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated AP2B1 data layer compared with 28 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher AP2B1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AP2B1 expression acts as an unfavorable survival marker, although some lineages such as COAD and LUAD show a favorable association.

LSCC, UCEC, and COAD are the cancer types where AP2B1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	III,IV	0.360	0.839	.001	62	view →
UCEC	OS	Tertile	II,III,IV	0.318	1.000	.001	56	view →
COAD	DFS	Median	All	1.000	0.921	.015	42	view →
CCRCC	DFS	Tertile	All	0.610	0.853	.019	3	view →
LUAD	OS	Median	All	0.987	0.937	.032	3	view →
PDAC	DFS	Tertile	IV	0.273	0.777	.038	3	view →
HNSC	DFS	Quartile	II,III,IV	0.522	0.744	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

AP2B1–LSCC (DFS)

Open the LSCC breakdown →